Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001230826 | SCV001403323 | likely benign | Severe combined immunodeficiency due to CARD11 deficiency; BENTA disease | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001332678 | SCV001525063 | uncertain significance | BENTA disease | 2020-01-21 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Genetic Services Laboratory, |
RCV001819930 | SCV002067449 | uncertain significance | not specified | 2020-07-20 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the CARD11 gene demonstrated a sequence change, c.583G>C, in exon 5 that results in an amino acid change, p.Val195Leu. This sequence change has been described in the gnomAD database with a frequency of 0.024% in the European sub-population (dbSNP rs747351557). The p.Val195Leu change has been reported in the heterozygous state in a patient with atopic dermatitis, asthma, diverticulitis, and Type 2 diabetes (PMID: 30170123). In vitro studies demonstrated reduced protein activation, suggesting a loss of function mechanism (PMID: 30170123). The p.Val195Leu change affects a moderately conserved amino acid residue located in a domain of the CARD11 protein that is not known to be functional. The p.Val195Leu substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences, the clinical significance of the p.Val195Leu change remains unknown at this time. |